CVS Caremark deal boosts Novo Nordisk's shares

Shares in Novo Nordisk NOVOb.CO are up 6.5% after CVS Health CVS.N said it would retain the Danish pharma group's Wegovy drug as a preferred product in its list of drugs eligible for reimbursement in the U.S.

CVS' pharmacy benefit management unit also plans to drop Eli Lilly's LLY.N weight-loss drug Zepbound from the list, the company says

Nordnet analyst Per Hansen attributes the share move to the CVS deal and adds that "perhaps Novo is slowly on its way out of the deep freeze"

Novo Nordisk's shares are down 26% year-to-date